Key facts
- This page summarizes Norman D. Schwartz's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Mar 2025, 17:03.
Norman D. Schwartz - 03 Mar 2025 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)
- Reporting relationship
- Chairman & CEO, Director, 10%+ Owner
- Issuer ticker
- BIO
- Reported as of
- 03 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Mar 2025, 17:03:00 UTC
- Prior SEC filing
- 10 Sep 2024
- Next SEC filing
- 03 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Norman Schwartz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Norman D. Schwartz filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 05 Mar 2025.
Change
- Previous filing in this sequence was filed on 10 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIO BIO.B
holding
Bio-Rad A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 438,238
- Date
- 03 Mar 2025
- Ownership
- Direct
BIO BIO.B
holding
Bio-Rad B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 361,466
- Date
- 03 Mar 2025
- Ownership
- Direct
BIO BIO.B
holding
Bio-Rad B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,006
- Date
- 03 Mar 2025
- Ownership
- By Spouse
- Footnotes
- F1
BIO BIO.B
holding
Bio-Rad B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,060,054
- Date
- 03 Mar 2025
- Ownership
- By Blue Raven Partners, L.P.
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIO BIO.B
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +11,671
- Change %
- Price
- $0.000000
- Shares after
- 11,671
- Date
- 03 Mar 2025
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 11,671
- Exercise price
- $256.45
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reporting person disclaims beneficial ownership of these shares.
Footnote F2
The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F3
The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.